Development of dual-acting prodrugs for circumventing multidrug resistance

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 3, 2009, Pages 995-1000

  Abu Ajaj, Khalid ^a   Kratz, Felix ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Albumin binding prodrug; Doxorubicin; Multidrug resistance

Indexed keywords

CATHEPSIN B; DOXORUBICIN; DRUG CARRIER; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HUMAN SERUM ALBUMIN; MALEIMIDE DERIVATIVE; ONT 093; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; BREAST CARCINOMA; CANCER MODEL; CONJUGATE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME SUBSTRATE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; TISSUE HOMOGENATE; TUMOR CELL; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CATHEPSIN B; CHEMISTRY, PHARMACEUTICAL; CYSTEINE; DOXORUBICIN; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; HUMANS; LYSINE; P-GLYCOPROTEINS; PEPTIDES; PHENYLALANINE; PRODRUGS; SERUM ALBUMIN;

EID: 58849118375     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.063     Document Type: Article

References (54)

1. Lehnert M. Anticancer Res. 18 (1998) 2225
2. Thomas H., and Coley H.M. Cancer Control 10 (2003) 159
3. Wang R.B., Kuo C.L., Lien L.L., and Lien E.J. J. Clin. Pharm. Ther. 28 (2003) 203
4. Leonessa F., and Clarke R. Endocr. Relat. Cancer 10 (2003) 43
5. Sikic B.I. Oncology (Williston Park) 13 (1999) 183
6. Sikic B.I., Fisher G.A., Lum B.L., Halsey J., Beketic-Oreskovic L., and Chen G. Cancer Chemother. Pharmacol. 40 Suppl. (1997) S13
7. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 361
8. Lu L., Leonessa F., Clarke R., and Wainer I.W. Mol. Pharmacol. 59 (2001) 62
9. Trock B.J., Leonessa F., and Clarke R. J. Natl. Cancer Inst. 89 (1997) 917
10. Mechetner E., Kyshtoobayeva A., Zonis S., Kim H., Stroup R., Garcia R., Parker R.J., and Fruehauf J.P. Clin. Cancer Res. 4 (1998) 389
11. Lee C.H. Curr. Med. Chem. Anticancer Agents 4 (2004) 43
12. Chan H.S., DeBoer G., Thiessen J.J., Budning A., Kingston J.E., O'Brien J.M., Koren G., Giesbrecht E., Haddad G., Verjee Z., Hungerford J.L., Ling V., and Gallie B.L. Clin. Cancer Res. 2 (1996) 1499
13. List A.F., Kopecky K.J., Willman C.L., Head D.R., Persons D.L., Slovak M.L., Dorr R., Karanes C., Hynes H.E., Doroshow J.H., Shurafa M., and Appelbaum F.R. Blood 98 (2001) 3212
14. Kaye S.B. Curr. Opin. Oncol. 10 Suppl. 1 (1998) S15
15. Advani R., Fisher G.A., Lum B.L., Hausdorff J., Halsey J., Litchman M., and Sikic B.I. Clin. Cancer Res. 7 (2001) 1221
16. Bates S., Kang M., Meadows B., Bakke S., Choyke P., Merino M., Goldspiel B., Chico I., Smith T., Chen C., Robey R., Bergan R., Figg W.D., and Fojo T. Cancer 92 (2001) 1577
17. Fischer V., Rodriguez-Gascon A., Heitz F., Tynes R., Hauck C., Cohen D., and Vickers A.E. Drug Metab. Dispos. 26 (1998) 802
18. Gruber A., Bjorkholm M., Brinch L., Evensen S., Gustavsson B., Hedenus M., Juliusson G., Lofvenberg E., Nesthus I., Simonsson B., Sjo M., Stenke L., Tangen J.M., Tidefelt U., Uden A.M., Paul C., and Liliemark J. Leuk. Res. 27 (2003) 323
19. Toppmeyer D., Seidman A.D., Pollak M., Russell C., Tkaczuk K., Verma S., Overmoyer B., Garg V., Ette E., Harding M.W., and Demetri G.D. Clin. Cancer Res. 8 (2002) 670
20. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., Bumol T.F., and Starling J.J. Cancer Res. 56 (1996) 4171
21. Starling J.J., Shepard R.L., Cao J., Law K.L., Norman B.H., Kroin J.S., Ehlhardt W.J., Baughman T.M., Winter M.A., Bell M.G., Shih C., Gruber J., Elmquist W.F., and Dantzig A.H. Adv. Enzyme Regul. 37 (1997) 335
22. Stewart A., Steiner J., Mellows G., Laguda B., Norris D., and Bevan P. Clin. Cancer Res. 6 (2000) 4186
23. Shepard R.L., Cao J., Starling J.J., and Dantzig A.H. Int. J. Cancer 103 (2003) 121
24. Rubin E.H., de Alwis D.P., Pouliquen I., Green L., Marder P., Lin Y., Musanti R., Grospe S.L., Smith S.L., Toppmeyer D.L., Much J., Kane M., Chaudhary A., Jordan C., Burgess M., and Slapak C.A. Clin. Cancer Res. 8 (2002) 3710
25. Oza A.M. Novartis Found. Symp. 243 (2002) 103
26. Abu Ajaj, K.; Biniossek, M. L.; Kratz, F. Bioconjugate Chem., submitted for publication.
27. Kratz F., Mueller-Driver R., Hofmann I., Drevs J., and Unger C. J. Med. Chem. 43 (2000) 1253
28. Kratz F., Warnecke A., Scheuermann K., Stockmar C., Schwab J., Lazar P., Drückes P., Esser N., Drevs J., Rognan D., Bissantz C., Hinderling C., Folkers G., Fichtner I., and Unger C. J. Med. Chem. 45 (2002) 5523
29. Mansour A.M., Drevs J., Esser N., Hamada F.M., Badary O.A., Unger C., Fichtner I., and Kratz F. Cancer Res. 63 (2003) 4062
30. Kratz F., and Beyer U. Drug Deliv. 5 (1998) 281
31. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. J. Control. Release 65 (2000) 271
32. Kratz F. Expert Opin. Invest. Drugs 16 (2007) 855
33. Graeser R., Chung D.E., Esser N., Moor S., Schachtele C., Unger C., and Kratz F. Int. J. Cancer 122 (2008) 1145
34. Kratz F., Mansour A., Soltau J., Warnecke A., Fichtner I., Unger C., and Drevs J. Arch. Pharm. (Weinheim) 338 (2005) 462
35. Ryppa C., Mann-Steinberg H., Fichtner I., Weber H., Satchi-Fainaro R., Biniossek M.L., and Kratz F. Bioconjug. Chem. 19 (2008) 1414
36. Chung D.E., and Kratz F. Bioorg. Med. Chem. Lett. 16 (2006) 5157
37. Schmid B., Chung D.E., Warnecke A., Fichtner I., and Kratz F. Bioconjug. Chem. 18 (2007) 702
38. Fiehn C., Kratz F., Sass G., Muller-Ladner U., and Neumann E. Ann. Rheum. Dis. 67 (2008) 1188
39. Warnecke A., Fichtner I., Sass G., and Kratz F. Arch. Pharm. (Weinheim) 340 (2007) 389
40. Dubowchik G.M., Firestone R.A., Padilla L., Willner D., Hofstead S.J., Mosure K., Knipe J.O., Lasch S.J., and Trail P.A. Bioconjug. Chem. 13 (2002) 855
41. Zhang C., Sarshar S., Moran E.J., Krane S., Rodarte J.C., Benbatoul K.D., Dixon R., and Mjalli A.M. Bioorg. Med. Chem. Lett. 10 (2000) 2603
42. Newman M.J., Rodarte J.C., Benbatoul K.D., Romano S.J., Zhang C., Krane S., Moran E.J., Uyeda R.T., Dixon R., Guns E.S., and Mayer L.D. Cancer Res. 60 (2000) 2964
43. Wolkenberg S.E., Wisnoski D.D., Leister W.H., Wang Y., Zhao Z., and Lindsley C.W. Org. Lett. 6 (2004) 1453
44. Sarshar S., Zhang C., Moran E.J., Krane S., Rodarte J.C., Benbatoul K.D., Dixon R., and Mjalli A.M. Bioorg. Med. Chem. Lett. 10 (2000) 2599
45. + 439.24, found 439.20.
46. Luyt L.G., and Katzenellenbogen J.A. Bioconjug. Chem. 13 (2002) 1140
47. Oku A., Yamaura Y., and Harada T. J. Org. Chem. 51 (1986) 3732
48. + 510.28, found 510.30.
49. Stein U., Walther W., Lemm M., Naundorf H., and Fichtner I. Int. J. Cancer 72 (1997) 885
50. +1546.63, found 1546.00.
51. +1190.52, found 1190.30.
52. 3+ 736.00, found 736.00. (see Supporting information of mass spectrum of 13).
53. 2O, 80% acetonitrile, 0.1% TFA, containing heptane-1-sulfonic acid (2 g/L); gradient: 0-10 min increase to 20% mobile phase B; 10-35 min increase to 100% mobile phase B; 35-40 min decrease to 100% mobile phase A; 40-60 min 100% mobile phase A, injection volume: 50 μL; column: symmetry 300 (250 × 4.6 mm) from Waters.
54. Preliminary toxicity studies of 13: Female nude mice were randomly distributed to the experimental groups (two/group) and injected with compound 13 (i.v, administered as a solution in 10% PEG 400/90% d-glucose buffer pH 5) at the following doses: (a) 33.6 mg/kg = 8 mg/kg doxorubicin equivalents, (b) 67.1 mg/kg = 16 mg/kg doxorubicin equivalents, or (c) 100.8 mg/kg = 24 mg/kg doxorubicin equivalents. The body weight change was observed daily for 13 days.